Canopy Growth shares plunge after analysts' warnings
Canopy Growth stock fell 10% last week after Rupesh Parikh, an analyst at the investment bank Oppenheimer, warned that investors should brace for heavy losses in the coming years.
Rupesh Parikh expects Canopy Growth to post losses of more than $500 million over the next two years, with the company’s return to profitability further off than many investors hope.
Canopy Growth is currently the largest cannabis company by market capitalization and a popular stock among cannabis investors, partly because of the company's substantial cash reserves. Canopy's financial strength stems primarily from the investment by $4 billion generated by Constellation Brands, which enabled the beer giant to hold nearly 40% of the cannabis producer.
Canopy’s operating losses are, however, reducing its cash position. Canopy generated a negative operating cash flow of 158 million Canadian dollars and a negative free cash flow of 372 million Canadian dollars in the last quarter. The company has struggled with both supply shortages in some markets and oversupply issues in others. This has led to revenue losses and lower margins. It is also acquiring companies at a rapid pace, an investment strategy that will strengthen its results in the medium to long term.
These problems have also caused upheaval among Canopy's leadership. Co-founder and co-CEO Bruce Linton, was ousted in July, partly due to Constellation Brands' frustration with Canopy's mounting losses. A new CEO has not yet been named
Despite this uncertainty regarding Canopy’s profitability, Rupesh Parikh predicts that the company’s shares will still trade at seven times its estimated 2021 revenue. For these reasons, the analyst recommends that investors hold off on buying shares until their valuation improves, but has declined to set a price target at this time.
-
Business4 weeks ago
Cronos Completes the Acquisition of CanAdelaar for 57.5 million euros
-
Cannabis in Quebec3 weeks ago
Cannabis: What France Could Learn from Quebec, Eight Years After Legalization
-
Cannabis in New Zealand3 weeks ago
Chronic Pain: New Zealand Is Testing Cannabis to Improve Sleep
-
Cannabis in France3 weeks ago
Dr. Pascal Douek, a tireless advocate for medical cannabis in France, has died
-
Business4 weeks ago
The Brazilian medical cannabis market continues to grow
-
Cannabis in France3 weeks ago
Medical cannabis: The Greens introduce two amendments to accelerate its widespread adoption
-
Cannabis in Spain4 weeks ago
Spain: Medical Cannabis Is Coming to About 50 Hospitals
-
Business4 weeks ago
British patients now have access to THCV-rich cannabis flowers


You must be logged in to post a comment Login